10-Q: Seres Therapeutics Reports Q1 2026 Financials Amidst Strategic Review

Seres Therapeutics filed its Q1 2026 Form 10-Q, detailing a net loss of $19.9 million and highlighting ongoing efforts to secure additional funding while pausing investment in the SER-155 Phase 2 study.

Summary

• Seres Therapeutics reported a net loss of $19.9 million for the first quarter ended March 31, 2026, compared to a net income of $32.7 million in the same period of 2025.
• Total revenue for Q1 2026 was $0.4 million, primarily from CARB-X grant reimbursements, a decrease from the prior year's $0.4 million which included TSA reimbursement income.
• Research and development expenses increased to $13.2 million from $11.8 million year-over-year, mainly due to platform costs and SER-155 program startup activities.
• General and administrative expenses decreased to $8.1 million from $11.9 million, attributed to lower headcount and reduced professional fees.
• The company has paused additional investment in the SER-155 Phase 2 study in allo-HSCT, while continuing to seek funding for it, and is prioritizing I&I disease programs.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, necessitating additional funding.
• The company implemented cost reduction actions, including a 30% workforce reduction in February 2026, incurring approximately $0.9 million in restructuring costs.
• The company is actively seeking a business development transaction, such as a partnership, to support SER-155's advancement and its broader pipeline.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss, the going concern warning, and the pausing of a key clinical program, despite some positive early-stage data.

Positives

• The company is evaluating SER-155 in an investigator-sponsored trial for immune checkpoint-related enterocolitis (irEC) and expects to report initial clinical results in the coming weeks.
• The SER-155 Phase 1b study in allo-HSCT showed a 77% relative risk reduction in bacterial BSIs compared to placebo.
• SER-155 was generally well tolerated in the Phase 1b study, with no observed treatment-related serious adverse events.
• The company received a CARB-X award in 2025 to support the development of SER-428, an oral liquid formulation for ICU patients.
• The company has a strong intellectual property estate related to live biotherapeutics, with patent protection extending through at least part of 2046 for key programs.

Negatives

• The company reported a net loss of $19.9 million for the quarter, continuing its trend of operating losses.
• Cash and cash equivalents decreased to $29.8 million as of March 31, 2026, from $45.8 million as of December 31, 2025.
• The company anticipates requiring additional funding following the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern.
• Investment in the SER-155 Phase 2 study has been paused due to the need for additional funding.
• The company implemented significant workforce reductions (25% in September 2025 and 30% in February 2026).
• The company has significant excess leased space, which may adversely affect its financial condition.
• The company is subject to a Nasdaq bid price requirement, having previously received a notice of non-compliance.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to its need for additional funding.
• The company may be unable to raise sufficient capital or secure a partnership, which could lead to further cost reductions, delays in product development, or winding down of operations.
• Clinical drug development is a risky, lengthy, and expensive process with an uncertain outcome; product candidates may fail to demonstrate safety and efficacy.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• Failure to obtain or delays in obtaining required regulatory approvals could prevent commercialization and materially impair revenue generation.
• Reliance on third parties for clinical trials introduces risks of unsatisfactory performance and potential delays.
• The company's product candidates are based on live biotherapeutics, a novel approach that may face regulatory hurdles due to the FDA's limited experience with this class of drugs.
• The company may not be able to protect its proprietary technology or obtain and maintain sufficient patent protection.
• The company has identified conditions and events that raise substantial doubt regarding its ability to continue as a going concern.

Future Outlook

The company anticipates requiring additional funding following the third quarter of 2026 and expects operating losses and negative cash flows to continue for the foreseeable future. Management plans to secure capital through financing or other strategic transactions, including potential business development transactions and selling shares under the at-the-market equity offering. The company is prioritizing its I&I disease programs and has paused additional investment in the SER-155 Phase 2 study pending further funding.

Management Comments

• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.
• We are actively seeking a business development transaction, which may include a partnership, to provide financial support and share in our vision to realize the clinical and commercial value of SER-155.
• Our current strategy prioritizes advancing our programs that target I&I indications.

Industry Context

StockSavvy.ai notes that Seres Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel live biotherapeutics. The company's financial situation, characterized by significant losses and a going concern warning, is not uncommon for clinical-stage biotechs. The strategic shift towards I&I disease programs and the pause in SER-155 development highlight the challenges of funding late-stage clinical trials in the current market.

Management Changes

Legal Proceedings

• Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint alleging infringement of U.S. Patent Nos. 9,433,652, 9,662,381, 9,808,519, 10,555,978, and 11,090,343 by the making, sale, and use of VOWST. The company believes the complaint is without merit and intends to defend itself vigorously.

Related Party Transactions

• Accounts receivable due from SPN (related party) were $0 as of March 31, 2026, down from $360 as of December 31, 2025.
• Accrued liabilities due to SPN (related party) were $3,278 as of March 31, 2026, unchanged from December 31, 2025, consisting of profit sharing payments, royalties, and VOWST post-marketing safety surveillance study costs.
• The company recognized $0 in TSA reimbursement income in Q1 2026, compared to $6,309 in Q1 2025, as the TSA concluded on December 31, 2025.
• The company received $360 from NESA (an affiliate of SPN) during Q1 2026 for transition services, compared to $56,709 in Q1 2025.

Stakeholder Impact

• Shareholders may experience continued stock price volatility and potential dilution if further equity financing is pursued.
• Employees may be impacted by workforce reductions and the ongoing financial challenges of the company.
• Creditors and suppliers may face increased risk due to the company's going concern status and need for additional funding.

Next Steps

• Continue seeking funding for the SER-155 Phase 2 study.
• Prioritize advancing I&I disease programs, starting with SER-603.
• Report initial clinical results for SER-155 in the investigator-sponsored trial for irEC in the coming weeks.
• Advance SER-428 development and design a Phase 1b trial in collaboration with Columbia University.
• Explore potential collaborations for I&I disease programs.

Key Dates

Recommendation

The company's financial position presents significant risks, including a going concern warning and paused clinical development. However, the potential of its live biotherapeutic platform and the early positive data for SER-155 warrant a cautious 'hold' rather than a 'sell'. Investors should monitor funding efforts and clinical trial progress closely.

Keywords

Seres Therapeutics, Form 10-Q, Quarterly Report, Live Biotherapeutics, Microbiome, SER-155, SER-603, SER-428, Clinical Trials, Biotechnology, SEC Filing, Financial Results, Going Concern, Funding